Large-scale Production & Purification Of Compounds With

生物技术股负责生物材料的生产和提纯。该单位承担广泛的生物生产任务，如原核生物和真核生物的大规模生长，以及生物化合物特别是蛋白质的生产和纯化。这些产品无法从商业来源获得，需要用于临床和结构研究。生物技术股能够通过实施生理和技术方法来处理这些不同的生产任务。高效率的工艺开发和生产是可能的，因为该股拥有两个综合要素：一个全面运作的多用途试验生产设施和进行研究和工艺开发的能力。在过去的一年中，该单位进行了大约200种不同的生产准备，包括：1）培养各种微生物，如重组大肠杆菌、重组巴斯德毕赤酵母、酵母、白喉棒状杆菌的突变株和炭疽杆菌的突变株; 2）繁殖大量哺乳动物细胞，如HeLa、CHO、HEK 293，昆虫细胞，如Sf 9和hi five; 3）从杂交瘤培养物和兔血清中纯化克量的重组铜绿假单胞菌外毒素A、来自炭疽杆菌的保护性抗原、C型葡萄球菌肠毒素、重组疟疾蛋白CSP、艰难梭菌毒素A、重组脂联素和几种抗体。在研究和开发竞技场方面，该股开展了以下主题的工作：1）继续开发更有效的大规模蛋白质回收方法，继续开展利用新型膨胀柱实施膨胀床吸附技术的工作：这种柱没有流量适配器和筛网，因此可以以更高的低速率处理更大浓度的生物质; 2）继续研究各种重组E. 3）继续开展与哺乳动物细胞有关的研究项目，旨在了解可悬浮生长的细胞与依赖锚定的细胞之间的遗传差异。4)本单位继续与LIFE、NICHD合作开发福氏志贺菌和炭疽杆菌的新疫苗，产品目前正在进行临床试验。5）本单位继续进行丝状真菌重组蛋白生产的研发项目。6)启动了一个旨在生产质粒DNA的新的研究和开发项目。

The Biotechnology Unit is responsible for the production and purification of biological material. The Unit undertakes a wide array of biological production tasks such as large scale growth of prokaryotes and eucaryotes, and production and purification of biological compounds especially proteins. These products, not available from commercial sources, are needed for clinical and structural studies. The Biotechnology Unit is capable of handling these various production tasks by implementing both physiological and technical approaches. Efficient process development and production is possible since the Unit possesses two integrated elements: a fully operational multi purpose pilot production facility and the capability of conducting research and process development. During the last year the unit performed approximately 200 different, production preparations including: 1) growing various microorganisms such as recombinant Escherichia coli, recombinant Pichia pastoris, yeasts, mutant strain of Corynebacteria diphtheria and mutant strain of Bacillus anthracis; 2) propagating large volumes of mammalian cells such as HeLa, CHO, HEK 293, insects cells such as Sf 9 and hi five; 3) purifying gram quantities of recombinant Pseudomonas aeruginosa exotoxin A, protective antigen from Bacillus anthracis, Staphylococcal enterotoxin type C, recombinant malarial protein CSP, Chlostridium difficile toxin A, recombinant adiponectin and several antibodies from hybridoma cultures and rabbit serum. On the research and development arena, the unit conducted work in the following topics: 1) Continued the development of more efficient methods for large scale protein recovery, work was continued on the implementation of expanded bed adsorption techniques utilizing new types of expanded column: this column does not have flow adaptors and screens and therefore can handle larger concentration of biomass at higher low rates; 2) continued its research aimed at understanding the glucose metabolism of various recombinant E. coli strains in an effort to find out why certain strains are more suitable for foreign protein production using microarrays technology and protein analysis; 3) continued its research project associated with mammalian cells aiming at understanding the genetic difference between cells that can grow in suspension, and cells that are anchorage dependent. 4) In collaboration with LDMI, NICHD, the unit continued the work on the development of new vaccine against Shigella flexneri and Bacillus anthracis, the products are currently in clinical trials.5) the unit continued its research and development project on the production of recombinant proteins from filamentous fungi. 6) A new research and development project aiming at the production of plasmid DNA was initiated.